Immatics reports 54% objective response rate in Phase 1b trial of IMA203 for metastatic melanoma, advancing to Phase 3 trial.
Read more
Immatics advances IMA203 cell therapy to Phase III for Melanoma, targeting progression-free survival as primary endpoint.
Read more
MeiraGTx's gene therapy AAV-GAD shows improved motor function in Phase II trial for Parkinson's Disease.
Read more
Allakos reports Phase 1 trial results showing subcutaneous AK006 is well-tolerated with 77% bioavailability in healthy volunteers.
Read more
Jazz Pharmaceuticals reports significant survival benefits in Phase 3 trial of Zepzelca and atezolizumab for extensive-stage small cell lung cancer.
Read more
FDA approves Roche's Itovebi for advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation, doubling progression-free survival.
Read more
FDA approves Accord BioPharma's IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like Psoriasis and Crohn's Disease.
Read more
FDA approves Pfizer's HYMPAVZIâ„¢ for Hemophilia A and B, offering a once-weekly subcutaneous treatment option without inhibitors.
Read more
Pfizer partners with Triana Biomedicines in a $1.5B deal to develop molecular glue degraders for cancer and other diseases.
Read more
FDA approves Novocure's Optune Lua for metastatic Non-Small Cell Lung Cancer, showing significant survival benefits in Phase 3 LUNAR study.
Read more
Cytosurge and Lexogen partner to enhance live-cell sequencing, integrating FluidFM® and LUTHOR HD for scalable transcriptomics research.
Read more
Boehringer Ingelheim partners with Circle Pharma to develop a novel cyclin inhibitor for hard-to-treat cancers, with potential milestone payments up to $607 million.
Read more
Johnson & Johnson's nipocalimab shows promise in adolescents with Myasthenia Gravis, supporting FDA review for adult use.
Read more
Lantern Pharma's LP-184 receives FDA Fast Track Designation for Glioblastoma, advancing in Phase 1A trials to improve treatment options for this aggressive brain cancer.
Read more
FDA approves Genentech's Itovebi for treating advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation, doubling progression-free survival.
Read more
Children's Hospital of Philadelphia receives $10 million ARPA-H award to develop a data-sharing tool for Cancer and Rare Diseases research.
Read more
Tencent invests $30 million in Insighta to advance AI-driven early cancer detection technology.
Read more
GEn1E Lifesciences reveals a novel dual signal modulator, GEn-1124, showing promise in treating inflammatory and autoimmune diseases by targeting the p38α:MK2 complex.
Read more
Eli Lilly invests $364M in the UK for its first European Gateway Lab, focusing on obesity and life sciences innovation.
Read more
Tevogen Bio's Phase I trial shows promising results for TVGN 489, an allogeneic T-cell therapy for SARS-CoV-2, with 99% viral elimination by day 14 and no Long COVID development in immunocompromised patients.
Read more
Hoth Therapeutics secures US patent for HT-ALZ, advancing Alzheimer's Disease treatment towards clinical trials.
Read more
Vizgen and Ultivue merge to enhance spatial multi-omics, combining genomics and proteomics technologies for deeper insights into disease mechanisms.
Read more
NEXGEL anticipates record Q3 2024 revenue of $2.85 million, marking a 133% year-over-year increase.
Read more
Madrigal Pharmaceuticals launches Rezdiffra, the first approved drug for Metabolic Dysfunction-Associated Steatohepatitis, with a targeted marketing strategy and plans for European expansion.
Read more
Klotho Neurosciences appoints Shire Pharmaceuticals co-founder Peter Moriarty as COO to advance cell and gene therapies for neurodegenerative diseases like Alzheimer's Disease and Parkinson's Disease.
Read more
